Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. As head of oncology, Legos will ...

Pfizer has partnered with Syapse to use the San Francisco-based software company's data-sharing network and insights platform to advance the development of precision cancer treatments.

Pfizer’s oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.